Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NOE-115 is an investigational monoamine modulator which has potential anti-inflammatory activity.”In the company’s words, NCT06385795 on ClinicalTrials.gov
- Tested for
- Menopause Syndrome, Menopause, Hot Flashes
- Main trialPhase 2
- “The purpose of this study is to determine the safety, tolerability, and preliminary effectiveness of NOE-115 on moderate to severe vasomotor symptoms (hot flashes) due to menopause in women.”In the company’s words, NCT06385795 on ClinicalTrials.gov
Other drugs for Menopause
- FezolinetantAstellas · Phase 3
- ElinzanetantBayer · Phase 3
- AsimadolineTioga Pharmaceuticals · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 13 Aug 2025 | A Study of NOE-115 in Women With Vasomotor Symptoms Due to Menopause |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026